IMMUNOVANT, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
IMMUNOVANT, INC. (IMVT) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.05% for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-06
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2026-06-30 was 4.05%, a 2.02% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-12-31 was 3.69%, a 13.99% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-09-30 was 4.06%, a 5.45% increase year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-06-30 was 3.97%, a 9.36% decline year-over-year.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2026 was 4.00%, a 7.62% decline from fiscal 2025.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 4.33%, a 20.28% increase from fiscal 2024.
- IMMUNOVANT, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 3.60%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|
| 2026-06-30 | 4.05% 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | 4.00% 10-K · filed 2026-05-20 | |||
| 2025-12-31 | 3.69% 10-Q · filed 2026-02-06 | 4.00% 10-Q · filed 2026-02-06 | ||
| 2025-09-30 | 4.06% 10-Q · filed 2025-11-10 | 4.00% 10-Q · filed 2025-11-10 | ||
| 2025-06-30 | 3.97% 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | 4.33% 10-K · filed 2026-05-20 | |||
| 2024-12-31 | 4.29% 10-Q · filed 2026-02-06 | 4.33% 10-Q · filed 2026-02-06 | ||
| 2024-09-30 | 3.85% 10-Q · filed 2025-11-10 | 4.34% 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | 4.38% 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | 3.60% 10-K · filed 2026-05-20 | |||
| 2018-12-31 | 2.97% 10-Q · filed 2020-02-14 | 2.97% 10-Q · filed 2020-02-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |